139 related articles for article (PubMed ID: 29949502)
21. Eltrombopag-Induced Acute Liver Failure in a Pediatric Patient: A Pharmacokinetic and Pharmacogenetic Analysis.
Marano M; Serafinelli J; Cairoli S; Martinelli D; Pisani M; Palumbo G; Cefalo MG; Cecchetti C; Di Nardo M; Falvella FS; Goffredo BM
Ther Drug Monit; 2018 Aug; 40(4):386-388. PubMed ID: 29683873
[TBL] [Abstract][Full Text] [Related]
22. Investigations of hydrazine cleavage of eltrombopag in humans.
Deng Y; Rogers M; Sychterz C; Talley K; Qian Y; Bershas D; Ho M; Shi W; Chen EP; Serabjit-Singh C; Gorycki PD
Drug Metab Dispos; 2011 Sep; 39(9):1747-54. PubMed ID: 21646438
[TBL] [Abstract][Full Text] [Related]
23. Eltrombopag for chronic immune thrombocytopenia.
Tanimoto T; Fukunaga S; Hori A; Yagasaki F; Ono S
Lancet; 2011 Jun; 377(9781):1919; author reply 1919-20. PubMed ID: 21641478
[No Abstract] [Full Text] [Related]
24. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Clinical Transporter-Mediated Drug-Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models.
Carter SJ; Chouhan B; Sharma P; Chappell MJ
CPT Pharmacometrics Syst Pharmacol; 2020 Apr; 9(4):211-221. PubMed ID: 32142598
[TBL] [Abstract][Full Text] [Related]
26. Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Saleh MI; Melhim SB; Al-Ramadhani HM; Alzubiedi S
Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):31-42. PubMed ID: 29948848
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
Garnock-Jones KP
BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
[TBL] [Abstract][Full Text] [Related]
28. Eltrombopag: a novel oral thrombopoietin receptor agonist.
Corman SL; Mohammad RA
Ann Pharmacother; 2010 Jun; 44(6):1072-9. PubMed ID: 20460556
[TBL] [Abstract][Full Text] [Related]
29. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
30. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
[TBL] [Abstract][Full Text] [Related]
31. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale.
Arnold DM; Jamula E; Heddle NM; Cook RJ; Hsia C; Sholzberg M; Lin Y; Kassis J; Blostein M; Larratt L; Amini S; Schipperus M; Carruthers J; Lane SJ; Li N; Kelton JG
Thromb Haemost; 2019 Mar; 119(3):500-507. PubMed ID: 30685874
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
Zhang Y; Kolesar JM
Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers.
Stangier J; Su CA; Schöndorfer G; Roth W
J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1355-64. PubMed ID: 11185634
[TBL] [Abstract][Full Text] [Related]
34. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
[TBL] [Abstract][Full Text] [Related]
35. Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.
Hayes S; Ouellet D; Zhang J; Wire MB; Gibiansky E
J Clin Pharmacol; 2011 Oct; 51(10):1403-17. PubMed ID: 21148042
[TBL] [Abstract][Full Text] [Related]
36. Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Determine the Disposition of Esculetin-7-O-Glucuronide and 4-Methylesculetin-7-O-Glucuronide.
Li Y; Song W; Ou X; Luo G; Xie Y; Sun R; Wang Y; Qi X; Hu M; Liu Z; Zhu L
Drug Metab Dispos; 2019 Mar; 47(3):203-214. PubMed ID: 30602435
[TBL] [Abstract][Full Text] [Related]
37. LC-MS/MS mediated absolute quantification and comparison of bile salt export pump and breast cancer resistance protein in livers and hepatocytes across species.
Li N; Palandra J; Nemirovskiy OV; Lai Y
Anal Chem; 2009 Mar; 81(6):2251-9. PubMed ID: 19209887
[TBL] [Abstract][Full Text] [Related]
38. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
39. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia.
Wire MB; Li X; Zhang J; Sallas W; Aslanis V; Ouatas T
Clin Pharmacol Ther; 2018 Dec; 104(6):1199-1207. PubMed ID: 29536526
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
